1.Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
3. Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter's Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 Pestle Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
4. Market Dynamics
4.1 Drivers
4.1.1 Growth in Cataract Volume
4.1.2 Availability of new drugs and devices
4.1.3 Demographic shift and impact of the prevalence of eye disease
4.2 Restraints
4.2.1 Economic Slowdown in developed markets
4.2.2 Increasing Healthcare Costs
4.3 Opportunities
4.3.1 Emerging markets present remarkable growth opportunities
4.3.2 Growing opportunities in developing economies
4.4 Challenges
4.4.1 Lack of awareness
4.4.2 Risk associated with the ocular diseases
5. North America Ophthalmic Drugs Market - By Drugs
5.1 Ophthalmic Swelling
5.2 Mydriasis Drugs
5.3 Ophthalmic Lubricants
5.4 Ophthalmic Inflammation Drugs
5.5 Ophthalmic Infection Drugs
5.6 Anti-Glaucoma Drugs
6. North America Ophthalmic Drugs Market - By Country
6.1.Introduction
6.2.USA
6.3.Canada
6.4. Mexico
7. North America Ophthalmic Drugs Market - Company Profiles
7.1 Roche
7.2 Pfizer
7.3 Novartis International,Inc.
7.4 Merck & Co,Inc.
7.5 Johnson and Johnson
7.6 GSK
7.7 Gene Signal
7.8 EyeGate Pharmaceuticals
7.9 CIBA Vision
7.10 Bristol-Myers Squibb
7.11 Bausch and Lomb
7.12 Ampio Pharma
8. North America Ophthalmic Drugs Market - Competitive Landscape
8.1 Market Share Analysis
8.2 Strategies Adopted by top companies
8.3 Mergers, Acquisitions, Collaborations & Agreements
9. Market Insights
9.1 Insights of Industry Experts
9.2 Investment Opportunities
9.3 Analyst Opinion
10. Appendix
10.1 List of Tables
10.2 List of Figures
